Human immunodeficiency virus and liver disease forum 2010: Conference proceedings

Authors


  • Potential conflict of interest: Unrestricted educational grants from pharmaceutical sponsors to support this meeting were provided by Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Three Rivers Pharmaceuticals, LLC, and Vertex Pharmaceuticals, Inc. Continuing Medical Education credit and content oversight were provided by Medical Education Resources, Inc. Dr. Sherman advises and received grants from Merck, Vertex, SciClone, and Roche. He advises Bristol-Myers Squibb, GlaxoSmithKline, Baxter, and Regulus. He received grants from Gilead, Boehringer Ingelheim, Siemens, and Anadys. He holds other interests with Pfizer, Tibotec, and Medpace.

  • The meeting participants included the following individuals: The chairman was Kenneth E. Sherman, M.D., Ph.D., University of Cincinnati. The cochairs were Raymond T. Chung, M.D., Harvard Medical School; and David L. Thomas, M.D., M.P.H., Johns Hopkins University. The speakers (invited and selected) were Meena Bansal, M.D., Mt. Sinai School of Medicine; Pablo Barreiro, M.D., Ph.D., Hospital Carlos III, Madrid, Spain; Mauricio Bonacini, M.D., California Pacific Medical Center, University of California San Francisco; Norbert Brau, M.D., Bronx Veterans Affairs Medical Center; Susan W. Brobst, Ph.D., National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); John T. Brooks, M.D., Ceners for Disease Control and Prevention; Kyong-Mi Chang, M.D., University of Pennsylvania; Harel Dahari, M.D., The University of Illinois; Mark Eckman, M.D., University of Cincinnati; Brian R. Edlin, M.D., M.P.H., SUNY Downstate College of Medicine; Russell Fleischer, PA-C, M.P.H., U.S. Food and Drug Administration; Judith Feinberg, M.D., University of Cincinnati; Lucia Gallego, M.D., Hospital Clinico San Carlos, Madrid, Spain; Elisa Garlassi, M.D., University of Modena and Reggio Emilia, Modena, Italy; Richard Green, M.D., Northwestern University; Maria Hernandez, M.D., University of Cincinnati; Jag Khalsa, Ph.D., National Institute on Drug Abuse, NIH; Luciana Kikuchi, M.D., University of Sao Paulo, Sao Paulo, Brazil; Nina Kim, M.D., University of Washington; David E. Kleiner, M.D., Ph.D., NIH; Dan Kuritzkes, M.D., Harvard Medical School; Christina Martin, Ph.D., University of Cincinnati; Anu Osinusi, M.D., M.P.H., NIH; Massimo Puoti, M.D., University of Brescia, Brescia, Italy; Nazia Qazi, M.D., Veterans Affairs Medical Center; Chip Schooley, M.D., University of California San Diego; Amy Shah, M.D., Virginia Commonwealth University; Gerald Sharp, M.D., NIAID, NIH; Richard Sterling, M.D., Virginia Commonwealth University; Peter G. Stock, M.D., Ph.D., University of California San Francisco; Robert Striker, M.D., University of Wisconsin School of Medicine and Public Health; Gyongi Szabo, M.D., University of Massachusetts; Chloe Thio, M.D., Johns Hopkins University; Glenn J. Treisman, M.D., Ph.D., Johns Hopkins University; Eugenia Vispo, M.D., Hospital Carlo III, Madrid, Spain; Joe Wang, Ph.D., National Institute on Alcohol Abuse and Alcoholism, NIH; Benjamin Westley, M.D., Brown University; and David Wyles, M.D., University of California San Diego.

Abstract

Liver disease continues to represent a critical mediator of morbidity and mortality in those with human immunodeficiency virus (HIV) infection. The frequent presence and overlap of concomitant injurious processes, including hepatitis C virus and hepatitis B virus infections, hepatoxicity associated with antiretroviral therapeutic agents, alcohol, and other toxins, in the setting of immunosuppression lead to rapid fibrotic progression and early development of end-stage liver disease. This conference summary describes the proceedings of a state-of-the-art gathering of international experts designed to highlight the status of current research in epidemiology, natural history, pathogenesis, and treatment of HIV and liver disease. (HEPATOLOGY 2011)

Ancillary